Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences (FBRX) Common Equity (2016 - 2020)

Historic Common Equity for Forte Biosciences (FBRX) over the last 5 years, with Q3 2020 value amounting to $20.3 million.

  • Forte Biosciences' Common Equity rose 262.12% to $20.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was $20.3 million, marking a year-over-year increase of 262.12%. This contributed to the annual value of -$4.8 million for FY2019, which is 10820.19% down from last year.
  • As of Q3 2020, Forte Biosciences' Common Equity stood at $20.3 million, which was up 262.12% from $24.9 million recorded in Q2 2020.
  • In the past 5 years, Forte Biosciences' Common Equity ranged from a high of $88.6 million in Q2 2017 and a low of -$132.9 million during Q1 2017
  • For the 5-year period, Forte Biosciences' Common Equity averaged around $21.1 million, with its median value being $40.7 million (2019).
  • Its Common Equity has fluctuated over the past 5 years, first skyrocketed by 15713.21% in 2017, then crashed by 10820.19% in 2019.
  • Forte Biosciences' Common Equity (Quarter) stood at -$124.4 million in 2016, then soared by 157.13% to $71.1 million in 2017, then fell by 18.2% to $58.1 million in 2018, then plummeted by 108.2% to -$4.8 million in 2019, then skyrocketed by 526.06% to $20.3 million in 2020.
  • Its Common Equity stands at $20.3 million for Q3 2020, versus $24.9 million for Q2 2020 and $2.1 million for Q1 2020.